Oct 12, 2021 8:30am EDT Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Sep 16, 2021 11:05am EDT Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
Aug 23, 2021 4:00pm EDT Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
Aug 12, 2021 5:15pm EDT Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
Aug 06, 2021 8:30am EDT Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
Aug 04, 2021 8:30am EDT Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
Jul 27, 2021 8:30am EDT Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
Jul 06, 2021 8:15am EDT Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
Jun 17, 2021 9:15am EDT PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
